# Effectiveness and Safety of Mesenchymal Stem Cell Therapy in Long COVID Patients

> **NCT06492798** · PHASE1,PHASE2 · RECRUITING · sponsor: **Changhai Hospital** · enrollment: 76 (estimated)

## Conditions studied

- Long COVID
- Post-Acute COVID-19 Syndrome

## Interventions

- **DRUG:** umbilical cord mesenchymal stem cell

## Key facts

- **NCT ID:** NCT06492798
- **Lead sponsor:** Changhai Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2025-07-01
- **Final completion:** 2026-08-31
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2024-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06492798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06492798, "Effectiveness and Safety of Mesenchymal Stem Cell Therapy in Long COVID Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06492798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*